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A RNA-Sequencing approach for 
the identification of novel long 
non-coding RNA biomarkers in 
colorectal cancer
Atsushi Yamada1,3, Pingjian Yu2, Wei Lin2, Yoshinaga Okugawa1,4, C. Richard Boland1 &  
Ajay Goel1
Long non-coding RNAs (lncRNAs) have been implicated in human pathology, however, their role in 
colorectal carcinogenesis have not been fully elucidated. In the current study, whole-transcriptome 
analysis was performed in 3 pairs of colorectal cancer (CRC) and matched normal mucosa (NM) by RNA 
sequencing (RNA-seq). Followed by confirmation using the Cancer Genome Atlas (TCGA) dataset, we 
identified 27 up-regulated and 22 down-regulated lncRNAs in CRC. Up-regulation of four lncRNAs, 
hereby named colorectal cancer associated lncRNA (CRCAL)-1 [AC021218.2], CRCAL-2 [LINC00858], 
CRCAL-3 [RP11-138J23.1] and CRCAL-4 [RP11-435O5.2], was further validated by real-time RT-
PCR in 139 colorectal neoplasms and matched NM tissues. Knockdown of CRCAL-3 and CRCAL-4 in 
colon cancer cells reduced cell viability and colony formation ability, and induced cell cycle arrest. 
TCGA dataset supported the associations of CRCAL-3 and CRCAL-4 with cell cycle and revealed a 
co-expression network comprising dysregulated lncRNAs associated with protein-coding genes. In 
conclusion, RNA-seq identified numbers of novel lncRNAs dysregulated in CRC. In vitro experiments and 
GO term enrichment analysis indicated the functional relevance of CRCAL-3 and CRCAL-4 in association 
with cell cycle. Our data highlight the capability of RNA-seq to discover novel lncRNAs involved in 
human carcinogenesis, which may serve as alternative biomarkers and/or molecular treatment targets.
It is estimated that more than 70% of the human genome is transcribed into RNA, but only up to 2% is translated 
to proteins; hence, majority of RNA do not serve as a blue print for protein coding genes. RNA molecules which 
do not encode proteins are called non-coding RNAs (ncRNAs), and historically, most of them in the past were 
considered as transcriptional noise. Based on their length, ncRNAs are divided into two subgroups; small ncR-
NAs which are shorter than 200 nucleotides, and long ncRNAs (lncRNAs) that consist of 200 nucleotides or more 
in length1–3. Recent decade has witnessed a growing recognition for the functional relevance of microRNAs, a 
subgroup of small ncRNAs, as transcriptional repressors by virtue of their interaction with the 3′UTR regions 
of their downstream target genes. MicroRNAs are known to be involved in cellular differentiation, proliferation 
and apoptosis, and their dysregulation is known to associate with various human malignancies4. In contrast to 
miRNAs, the biological role of lncRNAs still remain poorly understood, and are an active area of investigation. 
However, cell-type and developmental time-point specific expression patterns and conserved sequences of lncR-
NAs raise the possibility that they also possess functional significance in the biological context1–3. In fact, func-
tional importance of several lncRNAs have been recently elucidated. For example, HOTAIR recruits polycomb 
repressive complex 2 to specific target genes, leading to epigenetic re-programming, and its increased expres-
sion levels were linked to progression of breast and gastric cancers5,6. Another lncRNA, MALAT1, is known to 
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regulate gene expression and alternative splicing, and has been linked to lung and several other human cancers7. 
Nonetheless, majority of lncRNAs have not been well characterized. Given the abundance of lncRNAs existing in 
human genome, there are perhaps a number of uncharacterized lncRNAs that possibly play key roles in human 
cancers. Therefore, it would be important to identify and investigate novel lncRNAs involved in human carcino-
genesis, which are potentially relevant as biomarkers and/or molecular targets for treatment. RNA sequencing 
(RNA-seq) is an approach to analyze whole-transcriptome using the next generation sequencing technology, 
which enables to virtually reconstruct an entire transcriptome, including lncRNAs. With its advantages in 
terms of a greater dynamic range and the ability to discover novel transcripts, RNA-seq is capable of identifying 
unknown lncRNAs involved in human pathology8. Indeed, RNA-seq technology has been utilized to discover 
novel lncRNAs in various diseases including prostate9, breast10, and gastric11 cancers.
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths in the Unites States, and more 
than 50,000 patients die of this disease annually12. Although molecular alterations involved in CRC have been 
well-known in terms of genetic mutations as well as epigenetic alterations such as DNA methylation13,14, the role 
of lncRNAs and their dysregulation in colorectal carcinogenesis has yet not been fully elucidated.
In the current study, we conducted a systematic and comprehensive identification of novel lncRNAs involved 
in colorectal carcinogenesis. To this end, we performed RNA-seq using matched cancerous and non-cancerous 
human colon tissues, followed by the validation of dysregulated lncRNAs by analyzing the Cancer Genome Atlas 
(TCGA) database (http://cancergenome.nih.gov/) and by real-time RT PCR. The aim of this study was to identify 
novel lncRNAs associated with colorectal carcinogenesis as alternative biomarkers and/or treatment targets for 
CRC by using RNA-seq technology.
Results
RNA-seq read mapping. A splice-aware mapping solution was implemented for RNA-seq read alignment. 
The alignment index was built on hg19 genome (including 25 chromosomes and other 68 unplaced contigs) com-
bined with total junction flanking TRANSCRIPTOMIC sequence summarized from GENCODE, EMSEMBLE 
and REFSEQ annotations. The junction flanking sequence length was defined by the read length subtract 5. 
Novoalign+ V2.08.01 was used for alignment. Redundant mapping at the same locus for both genome and tran-
scriptome was consolidated as one single hit. The read count for each annotated transcript was then derived from 
mapped reads by Rsubread15. Some of the key statistics of read mapping is shown on Table 1.
Identification of dysregulated lncRNAs by RNA-seq. A heatmap generated from expression of differ-
entially expressed lncRNAs detected by edgeR on three pairs of matched CRC and NM tissues showed distinct 
expression patterns of these lncRNAs between CRC and NM tissues. (Fig. 1a) Heatmap plot for the expression of 
these lncRNAs on TCGA dataset is also shown in Fig. 1a. By analyzing in-house RNA-seq data, 72 lncRNAs were 
found to be significantly dysregulated in CRC compared to NM tissues. Of these, 27 of 36 up-regulated lncRNAs 
and 22 of 36 down-regulated lncRNAs were confirmed by TCGA dataset (Table 2). Dysregulation of CCAT116, 
UCA117, and MEG318 has been previously linked to CRC, while dysregulation of LINC0097419 and TRPM2-AS20 
have been reported in hepatocellular carcinoma and prostate cancer, respectively. In addition, RP11-115D19.1 
and TINCR have been functionally associated with certain biological contexts21,22. Thus, as a result of in-house 
RNA-seq and confirmation by TCGA dataset, we could identify 42 novel lncRNAs which have not been previ-
ously well documented. When we visualized the RNA-seq reads at each dysregulated lncRNA by using IGV, in 
contrast to many protein-coding genes showing much larger read counts, majority of dysregulated lncRNAs had 
very small read counts which were mostly less than 10 (Fig. 1b,c).
Validation of dysregulated lncRNAs in colorectal tumors by real-time RT-PCR. To validate the 
dysregulated expression of lncRNAs found by RNA-seq in more colorectal tumors, we performed real-time 
RT-PCR to examine the levels of four lncRNAs, AC021218.2, LINC00858, RP11-138J23.1 and RP11-435O5.2, in 
139 colorectal tumors including 134 CRCs and 5 colorectal adenomas (CAs), and 139 matched normal mucosae 
(NM) tissues. In line with the results of RNA-seq, levels of four lncRNAs examined were significantly higher in 
colorectal tumors compared to matched NM tissues (Fig. 2a). Given the association of these novel lncRNAs with 
CRC, we hereby name them as ColoRectal Cancer Associated LncRNAs (CRCAL)-1 [AC021218.2], CRCAL-2 
[LINC00858], CRCAL-3 [RP11-138J23.1], and CRCAL-4 [RP11-435O5.2]. Levels of CRCALs did not change 
among adenoma and stage I-IV CRCs, except for CRCAL-2 which showed significantly lower levels in stage IV 
compared to stage III CRCs. Thus, no stepwise increase during the tumor progression was observed (Fig. 2b).
Knockdown of CRCAL-3 and CRCAL-4 in colon cancer cells. To gain further insight into whether these 
dysregulated lncRNAs have any functional role in CRC, we performed knockdown of CRCAL-3 and CRCAL-4 
by transfecting siRNAs in colon cancer cells, HCT116 and SW620. As expected, levels of both CRCAL-3 or 
CRCAL-4 decreased significantly after transfection of siRNA specific for respective lncRNA, confirming their 
Numbers of reads CRC samples NM samples
Raw Illumina HiSeq 37622042 47125659
Unmapped −3443717 −11039389
Unannotated −20829243 −22681232
Total mRNA abundance 13349082 13405038
Table 1. Statistics of reads mapping.
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successful knockdown (Fig. 3a). CRCAL-3 knockdown resulted in decreased cell viability by MTT assay, reduced 
colony formation ability, and cell cycle arrest at G0/G1 in both cell lines. Knockdown of CRCAL-4 showed similar 
effects in HCT116 cells, however, it caused minimal inhibition of cell viability but no obvious effects on colony 
formation ability nor cell cycle progression in SW620 cells (Fig. 3b–d).
Analyses of CRCAL-3 and CRCAL-4 expression in TCGA dataset. To further validate the significance 
of CRCAL-3 and CRCAL-4 in colorectal carcinogenesis using an independent dataset, we again utilized RNA-seq 
data of 682 colon cancers and 41 normal tissues from TCGA database. First, we compared the expression levels of 
CRCAL-3 and CRCAL-4 between colon cancers and normal tissues, and as mentioned above, we confirmed the sig-
nificant up-regulation of two lncRNAs in colon cancers (Fig. 4a). Since we observed the relation of two lncRNAs to 
cell cycle by in vitro knockdown experiments, we next analyzed the association of either CRCAL-3 or CRCAL-4 with 
cell cycle. We performed the GO term enrichment analysis (Fig. 4b), and found that the ranks of correlation between 
CRCAL-3 (CRCAL-4) and cell cycle (GO:0007049) genes were significantly higher than those between CRCAL-3 
(CRCAL-4) and background genes, which indicates the significant association of these lncRNAs with cell cycle. 
Finally, we drew a co-expression network comprised of vertices, which represent differentially expressed lncRNAs or 
protein-coding genes from RNA-seq datasets, and edges, which represent the co-expression (measured by Pearson’s 
Figure 1. (a) Heatmap generated by RNA-seq data from our own sequencing (left) and TCGA (right) 
datasets showing the distinct expression pattern of lncRNAs in CRC and matched NM tissues. (b,c) Sequence 
information of RNA-seq data was visualized by IGV. Each row indicates paired colonic samples including CRC 
and matched NM from three patients. The vertical axis represents sequence reads at particular chromosomal 
position where the scale was large (0–1000) or small (0–5). While the reads for CRCAL-2 [LINC00858] (blue 
triangle) cannot be recognized with the large scale, nearby protein-coding genes, GHITM and C10orf99 (red 
triangles), showed abundant read counts (b). Although sequence reads for CRCAL-2 (blue arrow heads) was 
modest, its up-regulation was visible with the small scale (c).
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correlation) of lncRNAs and protein-coding genes in colon cancer tissues. As shown in Fig. 4c, some of hub lncRNAs 
in the network have been verified either by literatures (CCAT1 in16, MEG3 in18, LINC0097419 and TINCR in21,22) 
or by RT-PCR as well as in vitro knockdown in our experiments (CRCAL-1, CRCAL-2, CRCAL-3 and CRCAL-4). 
There are large overlaps between the target protein-coding genes of CRCAL-1, CRCAL-3 and CRCAL-4, therefore 
these three lncRNAs may function together in a pathway that is different than that of CRCAL-2.
Transcript ID Gene ID Gene Symbol logFC p-value FDR lncRNA Type FDR (TCGA)
ENST00000464746 ENSG00000172016 REG3A 7.812 0.002 0.019 retained_intron <0.001
ENST00000559321 ENSG00000259485 CTD-2147F2.1 7.719 <0.001 0.007 lincRNA <0.001
ENST00000521586 ENSG00000253929 CASC21 7.449 0.005 0.015 lincRNA <0.001
ENST00000436530 ENSG00000225680 AL163953.2 7.157 <0.001 0.019 lincRNA <0.001
ENST00000413290 ENSG00000224099 AC064834.1 6.954 <0.001 0.015 lincRNA <0.001
ENST00000514769 ENSG00000251026 RP11-138J23.1 6.55 0.002 0.037 lincRNA <0.001
ENST00000451622 ENSG00000231172 AC007099.1 6.463 0.002 0.052 antisense <0.001
ENST00000419196 ENSG00000230234 RP1-276N6.2 6.202 <0.001 0.081 lincRNA <0.001
ENST00000513572 ENSG00000251095 RP11-115D19.1 6.201 0.001 0.019 antisense <0.001
ENST00000476618 ENSG00000091436 pk 5.867 0.003 0.093 retained_intron <0.001
ENST00000456880 ENSG00000230061 TRPM2-AS 5.677 0.003 0.092 antisense <0.001
ENST00000560314 ENSG00000259485 CTD-2147F2.1 5.671 <0.001 0.093 lincRNA <0.001
ENST00000521815 ENSG00000254166 CASC19 5.595 <0.001 0.051 lincRNA <0.001
ENST00000532195 ENSG00000137699 TRIM29 5.541 0.002 0.11 retained_intron 0.018
ENST00000479258 ENSG00000172023 REG1B 5.526 0.002 0.128 retained_intron <0.001
ENST00000510419 ENSG00000249942 AC142293.3 5.309 0.002 0.146 antisense <0.001
ENST00000500112 ENSG00000247844 CCAT1 4.9 0.004 0.019 lincRNA <0.001
ENST00000446246 ENSG00000235669 AC004593.3 4.326 0.001 0.151 antisense <0.001
ENST00000531363 ENSG00000254560 BBOX 1-AS1 4.19 0.003 0.16 antisense <0.001
ENST00000445083 ENSG00000225328 LINC01594 4.071 0.003 0.188 antisense <0.001
ENST00000456253 ENSG00000228956 SATB1-AS1 4.044 0.001 0.166 antisense 0.007
ENST00000419422 ENSG00000232445 RP11-132A1.4 4.037 <0.001 0.091 antisense <0.001
ENST00000415469 ENSG00000229404 LINC00858 3.708 <0.001 0.166 lincRNA <0.001
ENST00000498352 ENSG00000090104 RGS1 3.646 0.003 0.155 retained_intron <0.001
ENST00000397381 ENSG00000214049 UCA1 3.602 <0.001 0.146 lincRNA <0.001
ENST00000433644 ENSG00000237857 RP11-435O5.2 3.354 <0.001 0.188 lincRNA 0.042
ENST00000377722 ENSG00000204876 AC021218.2 3.134 <0.001 0.192 lincRNA <0.001
ENST00000497872 ENSG00000253701 AL928768.3 −3.205 0.002 0.146 lincRNA <0.001
ENST00000522615 ENSG00000254042 CTC-558O2.1 −3.341 0.002 0.16 antisense <0.001
ENST00000531791 ENSG00000162241 SLC25A45 −3.344 0.003 0.188 retained_intron 0.045
ENST00000488268 ENSG00000121310 ECHDC2 −3.354 0.004 0.18 retained_intron 0.002
ENST00000548722 ENSG00000257194 RP11-567C2.1 −3.448 0.004 0.188 lincRNA <0.001
ENST00000452922 ENSG00000224081 LINC01057 −3.459 <0.001 0.166 lincRNA <0.001
ENST00000524052 ENSG00000253549 CA3-AS1 −3.712 0.004 0.145 antisense <0.001
ENST00000456403 ENSG00000226629 LINC00974 −3.771 0.002 0.143 lincRNA <0.001
ENST00000428573 ENSG00000226862 RP11-569A11.1 −3.89 <0.001 0.151 antisense 0.005
ENST00000464125 ENSG00000244383 FAM3D-AS1 −4.097 <0.001 0.142 antisense <0.001
ENST00000536094 ENSG00000251301 RP11-81H14.2 −4.101 <0.001 0.197 lincRNA <0.001
ENST00000448587 ENSG00000223573 TINCR −4.111 0.002 0.057 lincRNA <0.001
ENST00000488733 ENSG00000163399 ATP1A1 −4.144 0.004 0.145 retained_intron 0.012
ENST00000463617 ENSG00000100417 PMM1 −4.152 0.003 0.185 retained_intron 0.004
ENST00000464150 ENSG00000186417 GLDN −4.161 0.003 0.152 retained_intron <0.001
ENST00000533203 ENSG00000255186 RP11-514F3.5 −4.199 <0.001 0.162 sense_intronic <0.001
ENST00000559274 ENSG00000075413 MARK3 −4.243 <0.001 0.161 retained_intron 0.008
ENST00000529171 ENSG00000254718 CTD-2184C24.2 −4.351 0.003 0.168 antisense <0.001
ENST00000433071 ENSG00000237594 AP000251.3 −4.826 <0.001 0.093 antisense <0.001
ENST00000501708 ENSG00000245156 RP11-867G23.3 −4.883 0.004 0.087 lincRNA 0.021
ENST00000427901 ENSG00000235523 RP11-63P12.7 −5.119 <0.001 0.061 lincRNA <0.001
ENST00000398460 ENSG00000214548 MEG3 −5.238 <0.001 0.151 lincRNA <0.001
Table 2. LncRNAs dysregulated in CRC discovered by RNA-seq and confirmed by TCGA.
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Discussion
In the current study, we performed a systematic and comprehensive identification of dysregulated lncRNAs in 
CRC, and found four lncRNAs, CRCAL-1, CRCAL-2, CRCAL-3 and CRCAL-4, as novel lncRNAs involved in 
colorectal carcinogenesis. First, by using RNA-seq technology followed by analysis of TCGA dataset, we discov-
ered distinct lncRNA expression patterns between CRC and adjacent NM tissues. Furthermore, we could identify 
a number of candidate lncRNAs that were dysregulated in CRCs. Looking into RNA-seq data, the read depths for 
these lncRNAs were generally small. In fact, maximum read counts were less than 10 in most of our candidate 
lncRNAs. The small read depth can be caused by technical issues regarding RNA-seq. However, considering that 
the read depths of many protein-coding genes were much larger, the low read depths of lncRNAs is more likely 
to reflect the limited abundance of lncRNA molecules compared to those of mRNAs of protein-coding genes. In 
fact, out of 72 lncRNAs found by our in-house RNA-seq analysis, we were able to confirm the dysregulation of 49 
lncRNAs by utilizing TCGA dataset in 682 colon cancers. Moreover, we could further validate the up-regulation 
of four CRCALs in an independent cohort of 139 pairs of colorectal tumors and adjacent mucosa by means of 
real-time RT-PCR. Thus, although the low read depths made it difficult to distinguish lncRNA sequence from 
artifacts, and we used as little as three pairs of CRC and NM tissues for initial discovery by RNA-seq, our bioin-
formatics analyses enabled successful identification of novel lncRNAs associated with colorectal carcinogenesis. 
Collectively, RNA-seq approach appears to be a useful technology to discover novel lncRNAs that are involved in 
CRCs, and perhaps in other human cancers.
Although we identified novel CRCALs up-regulated in CRCs, their functional roles have not been previously 
elucidated. Since expression levels of all four CRCALs were elevated in CA tissues, and no obvious stepwise 
increase during the course of CRC progression was observed, these might be involved in the very early steps of 
neoplastic process. Given this early dysregulation of CRCALs in colorectal carcinogenesis, these noncoding RNAs 
might serve as potential biomarkers for early detection of CRC. Therefore, in the future studies, it is important to 
determine whether their dysregulation is also detectable by using noninvasively collected samples such as blood. 
In addition, it should be further investigated if CRCRLs have any association with known biomarkers of CRC 
such as microsatellite instability (MSI). In colon cancer cells, we observed that knockdown of CRCAL-3 and 
CRCAL-4 reduced cell viability and colony formation ability, and induced cell cycle arrest at G0/G1 phase. The 
associations of these lncRNAs with cell cycle were further supported by GO term enrichment analysis performed 
by using TCGA dataset, indicating the functional relevance of CRCAL-3 and CRCAL-4 in CRC. By analyzing the 
TCGA data, we also found a strong association between the expression levels of dysregulated lncRNAs and those 
of protein-coding genes forming a co-expression network. Although we only focused on functional relevance 
of two CRCALs, such co-expression network associating multiple lncRNAs and protein-coding genes may play 
important roles in driving colorectal neoplasia.
In conclusion, we conducted a systematic and comprehensive study to identify novel lncRNAs involved in 
colorectal carcinogenesis by using RNA-seq technology. We identified CRCAL-1, CRCAL-2, CRCAL-3 and 
CRCAL-4 as up-regulated lncRNAs in CRC in two independent cohorts. Functional relevance of CRCAL-3 and 
CRCAL-4 related to cell cycle was suggested by in vitro experiments as well as by GO term enrichment analy-
sis in the TCGA dataset. Our data highlight the capability of RNA-seq technology to discover novel lncRNAs 
involved in human carcinogenesis, which may serve as alternative biomarkers and/or molecular treatment targets 
for human cancers.
Figure 2. (a) Significant increase in transcripts levels of four lncRNAs, CRCAL-1 [AC021218.2], CRCAL-2 
[LINC00858], CRCAL-3 [RP11-138J23.1], and CRCAL-4 [RP11-435O5.2], were validated by real-time RT-PCR 
in 139 colorectal tumors including 134 CRCs and 5 CAs. (b) Levels of CRCAL-1, CRCAL-3 and CRCAL-4 were 
not significantly different, while CRCAL-2 levels differed with marginal significance among CAs and stage I to 
IV CRCs. By the Steel-Dwass test, levels of CRCAL-2 were significantly higher in stage III than in stage IV CRCs 
(*P < 0.05).
www.nature.com/scientificreports/
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Methods
Patients and clinical specimens. A total of 278 colorectal tissue specimens were analyzed in this study. 
These human tissues consisted of 134 CRCs, 5 CA and 139 matched adjacent NM which were obtained at the Mie 
University Hospital between January 2005 and July 2011. Characteristics of study subjects are summarized in 
Figure 3. Knockdown of CRCAL-3 and CRCAL-4 by siRNA in HCT116 and SW620 cells. (a) Transfection of siRNA 
for CRCAL-3 or CRCAL-4 induced significant repression of respective lncRNA transcripts. (b) MTT assay showed 
significant inhibition of cell viability after either CRCAL-3 or CRCAL-4 knockdown. (c) CRCAL-3 knockdown 
inhibited colony formation ability in HCT116 and SW620 cells. Colony formation was inhibited by CRCAL-4 
knockdown in HCT116 but not in SW620 cells. (d) Cell cycle analyses showed the G0/G1 arrest in HCT116 and 
SW620 cells after CRCAL-3 knockdown and in HCT116 cells after CRCAL-4 knockdown. (*P < 0.05, **P < 0.01).
www.nature.com/scientificreports/
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Supplementary Table S1. Tissue samples were collected during surgery and immediately stabilized by immersing 
them in RNAlater solution (Life Technologies, Carlsbad, CA, U.S.A), which were then stored at −80 °C until RNA 
extraction. Written informed consent was obtained from all study subjects, and the study protocol was approved 
by the Institutional Review Board of the Baylor Scott & White Research Institute, and all experiments were per-
formed in accordance with relevant guidelines and regulations.
Figure 4. Analyses of RNA-seq from TCGA dataset in 682 colon cancers and 41 NMs. (a) Expression levels 
of both CRCAL-3 and CRCAL-4 were significantly higher in colon cancer than in NM tissues. (b) GO term 
enrichment analysis confirmed the significant association of either CRCAL-3 or CRCAL-4 with cell cycle. 
(c) Differentially expressed lncRNAs and protein-coding genes from RNA-seq data formed a co-expression 
network in colon cancer tissues. Known and novel lncRNAs associated with colon cancer were identified.
www.nature.com/scientificreports/
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Cell culture and RNA interference mediated knockdown of lncRNAs. Colon cancer cell lines, 
HCT116 and SW620, were purchased from ATCC and were grown in Iscove’s modified Dulbecco’s medium 
(Invitrogen, Carlsbad, CA, U.S.A., catalog number 12440061) with 10% fetal bovine serum and 1% penicillin 
and streptomycin (Sigma-Aldrich, St. Louis, MO, U.S.A.), and maintained in a humidified 5% CO2 incuba-
tor at 37 °C. Custom designed siRNAs (Silencer Select siRNA) for CRCAL-3 [RP11-138J23.1] and CRCAL-4 
[RP11-435O5.2] and negative control siRNAs (Silencer Select Negative Control #1 siRNA) were purchased from 
Ambion (Foster City, CA, U.S.A.). Sequence of siRNAs specific for CRCAL-3 and CRCAL-4 are summarized in 
Supplementary Table S2. Cells were seeded at a density of 2 × 105 cells per well in 6-well plates and cultured for 
24 hours. Thereafter, each siRNA with the final concentration of 30 μM was transfected using the Lipofectamine® 
RNAiMAX Transfection Reagent (Invitrogen, catalog number 13778075). The cells were incubated for 48 hours 
and then subjected to RNA extraction or to additional experiments.
RNA extraction. RNA was extracted using miRNeasy Mini Kit (QIAGEN, Hilden, Germany) according 
to the manufacturer’s instruction. Briefly, 700 μL of QIAzol was added to samples and homogenized with a 
TissueLyser LT (QIAGEN) for RNAlater immersed tissues or by vortexing for 1 minute for cultured cells. After 
incubation of the homogenate for 5 minutes at room temperature, 140 μL chloroform was added and centrifuged 
at 12,000 g and at 4 °C for 15 minutes. Thereafter, transfer the upper aqueous phase to a new tube, and total RNA 
was extracted and eluted in 60 μL of RNase-free water using QIAcube (QIAGEN).
RNA sequencing (RNA-seq). RNA from 6 tissue samples including 3 CRCs and 3 matched adjacent NM 
were utilized for RNA-seq. RNA-seq was performed by Illumina HiSeq. 2000 platform. RNA-seq dataset was 
visualized by using the Integrative Genomics Viewer (IGV)23.
Real-time RT-PCR. Expression levels of 4 lncRNAs were examined by real-time RT-PCR in 139 pairs of colorectal 
tumors (134 CRCs and 5 CAs), and matched NM tissues. Primers used in this study are summarized in Supplementary 
Table S3. Reverse transcription was performed using 0.5 μg of total RNA with random hexamers and by Advantage 
RT-for-PCR Kit (Clontech, Mountain View, CA, U.S.A., catalog number 639506). Real-time PCR was conducted using 
Fast SYBR Green Master Mix (Applied Biosystems, Foster City, CA, U.S.A), and performed in duplicate on the StepOne 
Plus system (Applied Biosystems). Cycle threshold (Ct) values were calculated using StepOne Software v2.3 (Applied 
Biosystems), and the expression levels of lncRNAs were normalized to those of GAPDH and determined by the 2-∆Ct 
method in which ∆Ct were calculated as follows: ∆Ct = Ct (lncRNA of interest) − Ct (GAPDH).
Cell viability, cell cycle, and colony formation assays. Cell viability was determined using the MTT 
(3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide) assay (Sigma-Aldrich, catalog number M5655) 
as previously described24. Cells were transfected with either siRNA specific for CRCAL-3, CRCAL-4 or negative 
control siRNA, and re-plated at 5 × 103 in 96-well plates after 48 hours incubation. Optical density (OD) was 
determined at 565 nm by spectrophotometry (Infinite M200 PRO, Tecan, Männedorf, Switzerland) at 24, 48, 72, 
96 and 120 hours after re-plating. Cell cycle analysis was conducted 96 hours after siRNA transfection using the 
Cell Cycle Assay Kit (Merck Millipore, Billerica, MA, U.S.A., catalog number MCH100106) and the Muse Cell 
Analyzer (Merck Millipore) according to the manufacturer’s instructions. For colony formation assays, cells were 
re-plated at 5 × 102 in 6-well plates 72 hours after siRNA transfection. About 14 days later, cells were fixed and 
then stained by 0.5% crystal violet (Sigma-Aldrich, catalog number HT90132), and the number of colonies was 
counted using the GeneTools image analysis software (Syngene, Frederick, MD, U.S.A.). All experiments were 
conducted in at least two independent times.
TCGA data analyses. RNA-seq data for colon cancer (682 samples) as well as normal colon tissues (41 
samples) were downloaded from Cancer Genomics Hub. Differential gene expression analysis was performed 
on this dataset to verify the differentially expressed genes found from 3-pair RNA-Seq dataset. Large sample 
size of TCGA dataset enables us to perform correlation-based gene set enrichment analysis. Pearson’s correla-
tion test between lncRNA of interest and other gene was performed and ranked. GO term enrichment analysis 
was performed on the ranked gene set through topGO (http://www.bioconductor.org/packages/release/bioc/
html/topGO.html). TCGA dataset also enables us to build transcriptional co-expression network. The edges 
of the co-expression network were chosen based on the correlation between lncRNA and protein-coding gene 
across TCGA colon cancer samples (0.5% of strongest negative correlation and 0.5% of strongest position cor-
relation). The vertices of the co-expression network were chosen based on differentially expressed lncRNAs and 
protein-coding genes on both TCGA RNA-Seq dataset (FDR < 0.05) and 3-pair RNA-Seq dataset (FDR < 0.2).
Statistical analysis. Differential gene expression of RNA-seq data was analyzed by edgeR25. Read counts 
were fitted into Negative Binomial distribution with two GLM models: one model has only one regressor 
(patient), whereas the other model has two regressors (patient and treatment; CRC or NM). And then a pairwise 
comparison between matched CRC and NM was performed using likelihood ratio test between the two GLM 
models. Genes with a false discovery rate (FDR) less than 0.20 on 3 pairs RNA-Seq dataset (FDR < 0.05 on TCGA 
dataset) were considered to be significantly dysregulated. Statistical analyses to compare the lncRNA levels meas-
ured by real-time RT-PCR were carried out using JMP® 10 (SAS institute Inc., Cary, NC, U.S.A.). The Wilcoxon 
signed-rank test was conducted for the comparison between matched colorectal tumor and NM tissues. The 
Kruskal-Wallis test was performed to compare lncRNA levels among tumor stages, and the Steel-Dwass test was 
used to perform all-paired multiple comparisons. All experimental data were presented as mean ± SD, and the 
Student’s t-test was used to compare the differences between groups. All P-values were two-sided and a P-value of 
<0.05 was considered significant.
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Data availability. The datasets generated during and/or analysed during the current study are available in 
the GEO database at GSE104178.
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